Kathleen Behr, MD
Dermatology · Fresno, CANPI 1104812452
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $84,461 of the $138,528 with a category attached, or 61.0%. AbbVie accounts for 76.8% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2023 at $33,927 and has fallen 90.7% since, to $3,171 in 2025. Among dermatology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 379 payments — averaging $365.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$106K
- Merz North America, Inc.$31K
- Galderma Laboratories, L.p.$645
- Revance Therapeutics, Inc.$578
- Organogenesis Inc.$106
- Sientra, Inc.$75
- plus $201 from 7 others
Across 19 payments — averaging $4319.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$82K
What the payments were for
- Consulting fees$24,11817%
- Speaking & faculty fees$84,46161%
- Travel & lodging$16,42512%
- Food & beverage$13,44510%
- Education$780%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 243 | $106,376 |
| Merz North America, Inc. | 89 | $30,547 |
| Galderma Laboratories, L.p. | 18 | $645 |
| Revance Therapeutics, Inc. | 16 | $578 |
| Organogenesis Inc. | 3 | $106 |
| Sientra, Inc. | 1 | $75 |
| Solta Medical, A Division Of Bausch Health US, LLC | 2 | $51 |
| Genentech USA, Inc. | 2 | $34 |
| Surgenex LLC | 1 | $34 |
| Sun Pharmaceutical Industries Inc. | 1 | $24 |
| DUSA Pharmaceuticals, Inc. | 1 | $21 |
| Regeneron Healthcare Solutions, Inc. | 1 | $20 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$138,528 in reported general payments places this provider in the 95th percentile of 1,875 dermatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ValacyclovirValacyclovir Hcl | 43 | $726 |
| Fluocinonide | 16 | $534 |
| Ketoconazole | 13 | $209 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Fresno
- John BoswellFresno$777K
- Paul YamauchiSanta Monica$2.9M
- Jennifer SoungSanta Ana$2.8M
- Robert GreenbergLivermore$2.6M
- Neal BhatiaSan Diego$2.5M
- April ArmstrongLos Angeles$2.3M
- Jeffrey CrowleyBakersfield$2.1M
- Jashin WuCorona$2M
- Raja SivamaniSacramento$1.9M
- Tien NguyenFountain Valley$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.